Natixis Advisors LLC Acquires 2,360 Shares of Privia Health Group, Inc. (NASDAQ:PRVA)

Natixis Advisors LLC raised its position in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 18.1% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,409 shares of the company’s stock after purchasing an additional 2,360 shares during the period. Natixis Advisors LLC’s holdings in Privia Health Group were worth $301,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. First Horizon Advisors Inc. grew its stake in shares of Privia Health Group by 53.8% in the fourth quarter. First Horizon Advisors Inc. now owns 1,807 shares of the company’s stock worth $35,000 after purchasing an additional 632 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Privia Health Group by 7,833.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,380 shares of the company’s stock worth $47,000 after acquiring an additional 2,350 shares during the last quarter. Financial Management Professionals Inc. bought a new position in shares of Privia Health Group during the fourth quarter valued at $51,000. Quarry LP raised its position in shares of Privia Health Group by 344.6% in the 3rd quarter. Quarry LP now owns 3,268 shares of the company’s stock worth $60,000 after purchasing an additional 2,533 shares during the last quarter. Finally, Neo Ivy Capital Management bought a new position in Privia Health Group in the 3rd quarter worth about $66,000. 94.48% of the stock is owned by hedge funds and other institutional investors.

Privia Health Group Price Performance

PRVA stock opened at $22.59 on Friday. The company has a market capitalization of $2.72 billion, a PE ratio of 225.92, a P/E/G ratio of 3.47 and a beta of 0.85. Privia Health Group, Inc. has a 12 month low of $15.92 and a 12 month high of $26.04. The firm’s 50-day moving average is $23.80 and its 200 day moving average is $21.16.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Macquarie initiated coverage on Privia Health Group in a report on Monday, December 16th. They issued an “outperform” rating and a $25.00 price objective for the company. Piper Sandler upped their price target on shares of Privia Health Group from $25.00 to $40.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Stephens reissued an “overweight” rating and issued a $26.00 price target on shares of Privia Health Group in a report on Thursday, January 2nd. Needham & Company LLC restated a “buy” rating and set a $30.00 price objective on shares of Privia Health Group in a research report on Friday, March 21st. Finally, Canaccord Genuity Group upped their price target on shares of Privia Health Group from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Friday, February 28th. One research analyst has rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $26.67.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.